Product Description
For Solid Tumors Harboring NTRK Fusion (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03215511)
Mechanisms of Action: TRK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-004246-20 |
2017-004246-20 | P1 |
Completed |
Oncology Unspecified |
2023-01-30 |
23% |
2025-07-06 |
Treatments |